Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Akin

Showing results (121-130 of 203) with videos related to

Pageof 21
Sort By:
Annals of the Rheumatic Diseases|February 24, 2022
Efficacy of COVID-19 vaccines in patients taking immunosuppressantsChen Shen, Malcolm Risk, Elena Schiopu, et al.
British Journal of Haematology|August 22, 2003
Diagnosis and treatment of systemic mastocytosis: state of the artPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Leukemia Research|July 23, 2008
Lenalidomide therapy in systemic mastocytosisHanneke C Kluin-Nelemans, Veronika Ferenc, Jaap J van Doormaal, et al.
Leukemia Research|April 12, 2003
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 26, 2022
Remission of indolent systemic mastocytosis in the absence of targeted therapyGregory M Constantine, Dean D Metcalfe, Cem Akin, et al.
Leukemia Research|June 13, 2003
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRIArnold S Kirshenbaum, Cem Akin, Yalin Wu, et al.
Blood|September 25, 2003
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeAmy D Klion, Jamie Robyn, Cem Akin, et al.
Leukemia & Lymphoma|December 27, 2019
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019Michel Arock, Karl Sotlar, Jason Gotlib, et al.
Blood|April 5, 2003
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessAmy D Klion, Pierre Noel, Cem Akin, et al.
Clinical Case Reports|September 15, 2018
Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosisIris M Otani, Ryan W Carroll, Phoebe Yager, et al.
Pageof 21

Showing results (121-130 of 203) with videos related to

Sort By:
Pageof 21
Annals of the Rheumatic Diseases|February 24, 2022
Efficacy of COVID-19 vaccines in patients taking immunosuppressantsChen Shen, Malcolm Risk, Elena Schiopu, et al.
British Journal of Haematology|August 22, 2003
Diagnosis and treatment of systemic mastocytosis: state of the artPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Leukemia Research|July 23, 2008
Lenalidomide therapy in systemic mastocytosisHanneke C Kluin-Nelemans, Veronika Ferenc, Jaap J van Doormaal, et al.
Leukemia Research|April 12, 2003
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 26, 2022
Remission of indolent systemic mastocytosis in the absence of targeted therapyGregory M Constantine, Dean D Metcalfe, Cem Akin, et al.
Leukemia Research|June 13, 2003
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRIArnold S Kirshenbaum, Cem Akin, Yalin Wu, et al.
Blood|September 25, 2003
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeAmy D Klion, Jamie Robyn, Cem Akin, et al.
Leukemia & Lymphoma|December 27, 2019
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019Michel Arock, Karl Sotlar, Jason Gotlib, et al.
Blood|April 5, 2003
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessAmy D Klion, Pierre Noel, Cem Akin, et al.
Clinical Case Reports|September 15, 2018
Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosisIris M Otani, Ryan W Carroll, Phoebe Yager, et al.
Pageof 21